ClinicalTrials.gg
RecruitingNCT07523555ADAPT-HEMUpdated Apr 13, 2026

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

A Phase 1/2 interventional study of Autologous CD19/CD22 dual-target CAR-T module and Autologous CD19/CD20 dual-target CAR-T module in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL and Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, sponsored by Beijing Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Beijing Biotech · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 102 studies in Burkitt Lymphoma with a site in China — 58 open to participants now, 62 under way, 4 of them phase 3. Burkitt Lymphoma · China.

Planned enrollment
11th of 100
96 · median 24
Started
2026
with 10 others
Phase 1/2
21 of 102
9 open now
Primary completion
2027-03
later than 31 of 61 live
Registered
94th of 102
by date

Among the 102 studies in Burkitt Lymphoma with a site in China, this one is the 11th largest by planned enrollment of the 100 interventional ones that give a count, is one of 11 that started in 2026, is one of 21 in phase 1/2, reaches primary completion later than 31 of the 61 other live ones, and was the 94th registered.

Burkitt Lymphoma

977 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

58 of the 102 studies in Burkitt Lymphoma with a site in China are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 42 (32%) set no upper age limit and 77 (58%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Burkitt Lymphoma with a site in China, or all of them as a file.
02

Study summary

Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies. After central antigen co-expression screening, participants are assigned to the most appropriate active dual-target module: CD19/CD22, CD19/CD20, BCMA/CD19, BCMA/CD38, BCMA/GPRC5D, CD33/CD123, CD33/CLL1, or CD5/CD7. Phase 1 determines safety, dose-limiting toxicities, and the recommended phase 2 dose for each module; phase 2 estimates preliminary antitumor activity, including overall response rate and MRD-negative response.

Lymphodepletion with fludarabine/cyclophosphamide precedes infusion. The design is intended to reduce antigen escape by matching disease biology and target co-expression to a rational dual-target strategy.

Read the detailed description

Rationale. Relapse after single-target CAR-T therapy is often driven by antigen down-regulation, lineage plasticity, or pre-existing subclonal heterogeneity. A dual-target framework attempts to preserve depth of response while lowering the probability of escape through loss of one surface antigen. This example therefore uses a master protocol with disease-specific target modules rather than a one-size-fits-all construct. Screening and target selection. All participants undergo central immunophenotyping on bone marrow, peripheral blood, and/or involved tissue within 21 days before enrollment. A module is considered eligible when both antigens are detected on malignant cells by validated flow cytometry or equivalent assay and the anticipated on-target/off-tumor risk is acceptable. If more than one module qualifies, the target selection committee ranks options by disease-specific biology, antigen density, prior antigen-directed therapy, predicted escape risk, and manufacturability.

Treatment schema. Participants undergo leukapheresis, optional bridging therapy, fludarabine/cyclophosphamide lymphodepletion, and infusion of the selected dual-target CAR-T module on Day 0.

Depending on the module, the dual-target strategy may be delivered as a tandem/bicistronic product, compound product, or predefined sequential paired infusion if that is safer or more manufacturable for that antigen pair. Participants are monitored intensively through Day 28, followed for efficacy through Month 24, and may enter long-term gene-modified cell safety follow-up for up to 15 years if required by the final regulatory strategy.

03

Conditions studied

  • Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
  • Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
  • Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
  • BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
  • T-lymphoblastic Lymphoma
  • Peripheral T-cell Lymphoma

Keywords

  • BCMA
  • biomarker-selected
  • CD19
  • CD20
  • CD22
  • CD33
  • CD38
  • CD123
  • CD5
  • CD7
  • CLL1/CLEC12A
  • dual-target CAR-T
  • GPRC5D
  • hematologic malignancy
  • MRD negativity
  • antigen escape
  • umbrella trial
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years at the time of consent.
  • or cytologically confirmed eligible disease: B-ALL; B-cell NHL/CLL/SLL; multiple myeloma/plasma cell leukemia; AML/high-risk MDS/BPDCN; or T-ALL/T-LBL/peripheral T-cell lymphoma.
  • disease after at least 2 , or no curative/approved standard option judged appropriate by the investigator.
  • Central laboratory confirmation that at least one active dual-target module is suitable based on malignant-cell antigen co-expression and safety review.
  • Measurable or otherwise evaluable disease by disease-specific response criteria.
  • performance status 0 to 2.
  • Adequate organ function: >= 45%; >= 40 mL/min; /ALT \<= 3 x ; total \<= 1.5 x ULN unless due to Gilbert syndrome; oxygen saturation >= 92% on room air.
  • Adequate hematologic reserve unless cytopenia is clearly disease-related.
  • Ability to undergo leukapheresis and willingness to comply with study procedures and follow-up.
  • If prior HSCT: at least 100 days from transplant, no uncontrolled , and no systemic above physiologic replacement.
  • Negative pregnancy test for participants of and agreement to use effective during protocol-defined risk periods.
  • Written obtained before any study-specific procedure.

Exclusion criteria

Exclusion Criteria:

  • - Active uncontrolled infection, including uncontrolled bacterial, fungal, or viral infection, or clinical sepsis.
  • Active symptomatic CNS involvement requiring escalating therapy; previously treated/stable CNS disease may be allowed if defined prospectively in the final protocol.
  • Prior gene-modified cellular therapy within 12 weeks before leukapheresis, or unresolved >= Grade 3 toxicity from prior anticancer therapy
  • Need for urgent cytoreduction such that manufacturing delay would create unacceptable clinical risk.
  • Active disease requiring systemic , except limited replacement-dose or protocol-permitted topical/inhaled therapy.
  • Prior solid organ transplant.
  • cardiovascular disease, uncontrolled arrhythmia, decompensated heart failure, myocardial infarction within 6 months, or recent stroke within 6 months.
  • Uncontrolled , , or viremia.
  • Pregnancy or breastfeeding.
  • Another active requiring systemic therapy, unless low-risk and definitively treated per protocol-defined exceptions.
  • Known to fludarabine, cyclophosphamide, or critical product .
  • Inability to manufacture a releaseable CAR-T product or failure to meet module-specific product-release criteria.
  • Any medical, psychiatric, or social condition that, in the investigator's judgment, would increase risk, impair compliance, or confound interpretation of study results.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Arm A1 CD19/CD22

    B-ALL, DLBCL, FL, MCL, PMBCL, CLL/SLL, or Richter transformation with confirmed CD19-positive / CD22-positive disease.

    Biological: Autologous CD19/CD22 dual-target CAR-T module

  • Experimental
    Arm A2 CD19/CD20

    B-NHL or CLL/SLL with CD19-positive / CD20-positive disease, especially mature B-cell phenotype or relapse after prior CD19-directed therapy.

    Biological: Autologous CD19/CD20 dual-target CAR-T module

  • Experimental
    Arm B1 BCMA/CD19

    Multiple myeloma or plasma cell leukemia with BCMA-positive disease plus evidence of a CD19-positive minor clone, precursor phenotype, or marked clonal heterogeneity.

    Biological: Autologous BCMA/CD19 dual-target CAR-T module

  • Experimental
    Arm B2 BCMA/CD38

    Multiple myeloma or plasma cell leukemia with BCMA-positive / CD38-positive disease and a plasma-cell-dominant phenotype.

    Biological: Autologous BCMA/CD38 dual-target CAR-T module

  • Experimental
    Arm B3 BCMA/ GPRC5D

    Multiple myeloma or plasma cell leukemia with BCMA-positive / GPRC5D-positive disease, especially after prior BCMA exposure or with high escape risk.

    Biological: Autologous BCMA/GPRC5D dual-target CAR-T

  • Experimental
    Arm C1 CD33/CD123

    AML, high-risk MDS, or BPDCN with CD33-positive / CD123-positive disease

    Biological: Autologous CD33/CD123 dual-target CAR-T module

  • Experimental
    Arm C2 CD33/CLL1

    AML with CD33-positive / CLL1(CLEC12A)-positive disease, particularly stem-cell-rich or measurable residual disease patterns.

    Biological: Autologous CD33/CLL1 dual-target CAR-T module

  • Experimental
    Arm D1 CD5/CD7

    T-ALL, T-LBL, or peripheral T-cell lymphoma with dual CD5-positive / CD7-positive expression and a feasible fratricide-mitigation plan.

    Biological: Autologous CD5/CD7 dual-target CAR-T module

Interventions

  • BiologicalAutologous CD19/CD22 dual-target CAR-T module

    Biological: Autologous CD19/CD22 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide.

  • BiologicalAutologous CD19/CD20 dual-target CAR-T module

    Biological: Autologous CD19/CD20 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide.

  • BiologicalAutologous BCMA/CD19 dual-target CAR-T module

    Biological: Autologous BCMA/CD19 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide.

  • BiologicalAutologous BCMA/CD38 dual-target CAR-T module

    Biological: Autologous BCMA/CD38 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide.

  • BiologicalAutologous BCMA/GPRC5D dual-target CAR-T

    Biological: Autologous BCMA/GPRC5D dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide

  • BiologicalAutologous CD33/CD123 dual-target CAR-T module

    Biological: Autologous CD33/CD123 dual-target CAR-T module (simultaneous or planned sequential paired infusion, module-specific) after lymphodepletion.

  • BiologicalAutologous CD33/CLL1 dual-target CAR-T module

    Biological: Autologous CD33/CLL1 dual-target CAR-T module after lymphodepletion with fludarabine/cyclophosphamide.

  • BiologicalAutologous CD5/CD7 dual-target CAR-T module

    Biological: Autologous CD5/CD7 dual-target CAR-T module (including sequential paired infusion if needed for manufacturing/safety) after lymphodepletion.

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs) by module and dose level

    Time frame: 28 days

  2. Incidence of Grade 3 or higher cytokine release syndrome (CRS)

    Time frame: 28 days

Secondary outcomes

  1. Complete response CR

    Time frame: 6 Months

  2. MRD-negative response rate by validated disease-specific assay

    Time frame: 90 days

  3. Duration of response (DoR)

    Time frame: 24 months

  4. Overall survival (OS)

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2026
First posted
Apr 13, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Mar 14, 2027
CompletionEst.
Feb 17, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07523555
Lead sponsor
Beijing Biotech
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Mar 2, 2026
Primary completion
Mar 14, 2027 (estimated)
Completion
Feb 17, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

shan S Lu, Phd
Contact
Seni-Lu@beijing-biotech.com
+86 13076790030

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion